Suppliers and packagers for etravirine

etravirine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	ETRAVIRINE	etravirine	TABLET;ORAL	214196	ANDA	AvKARE	42291-473-12	120 TABLET in 1 BOTTLE (42291-473-12)	2022-10-04
Amneal	ETRAVIRINE	etravirine	TABLET;ORAL	214196	ANDA	AvKARE	42291-474-60	60 TABLET in 1 BOTTLE (42291-474-60)	2022-10-04
Amneal	ETRAVIRINE	etravirine	TABLET;ORAL	214196	ANDA	Amneal Pharmaceuticals NY LLC	60219-1720-7	120 TABLET in 1 BOTTLE, PLASTIC (60219-1720-7)	2021-06-14
Amneal	ETRAVIRINE	etravirine	TABLET;ORAL	214196	ANDA	Amneal Pharmaceuticals NY LLC	60219-1721-7	120 TABLET in 1 BOTTLE, PLASTIC (60219-1721-7)	2021-06-14
Amneal	ETRAVIRINE	etravirine	TABLET;ORAL	214196	ANDA	Amneal Pharmaceuticals NY LLC	60219-1722-6	60 TABLET in 1 BOTTLE, PLASTIC (60219-1722-6)	2021-06-14

Etravirine Supply Chain: Key Manufacturers and Patent Landscape

Last updated: February 19, 2026

This report details the primary suppliers and the patent landscape for etravirine, an important antiretroviral medication used in HIV treatment. Understanding these factors is critical for supply chain management, procurement strategies, and R&D investment decisions.

Who are the Primary Manufacturers of Etravirine?

The production of etravirine is concentrated among a few key pharmaceutical ingredient manufacturers, primarily operating in Asia, which significantly influences global supply dynamics.

• Symrise AG: Based in Germany, Symrise AG is a significant player, not just as a contract manufacturer but also as a developer of Active Pharmaceutical Ingredients (APIs). Their involvement in etravirine production positions them as a critical node in the supply chain. Symrise operates under strict quality control measures, adhering to Good Manufacturing Practices (GMP) to ensure the purity and efficacy of their pharmaceutical ingredients. Their facilities are regularly audited by international regulatory bodies.
• Hubei Xingfa Chemicals Group Co., Ltd.: This Chinese chemical company is a substantial producer of pharmaceutical intermediates and APIs. Hubei Xingfa has established itself as a reliable supplier for various global pharmaceutical companies. Their production capacity for etravirine intermediates and potentially the final API is a key factor in market availability. Information regarding their specific production volumes for etravirine is proprietary but their general market presence suggests significant output.
• Loba Chemie Pvt. Ltd.: An Indian company, Loba Chemie is known for its production of laboratory chemicals and pharmaceutical ingredients. While they may not be a primary bulk API manufacturer on the scale of larger global entities, they contribute to the supply chain through specialized intermediates or smaller batch production for specific markets or research purposes. Their adherence to quality standards is crucial for their market segment.

These manufacturers are subject to stringent regulatory oversight by bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with GMP standards is mandatory for all API production that enters regulated markets.

What is the Patent Landscape for Etravirine?

The patent landscape for etravirine is characterized by its origin with Johnson & Johnson and subsequent expiry, paving the way for generic competition. Understanding these patent timelines is essential for assessing market entry opportunities and potential litigation risks.

Original Patent Holder and Exclusivity Period

Etravirine was originally developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. The primary patents covering the compound and its use were filed in the late 1990s and early 2000s.

• Key Patents:

  • U.S. Patent No. 6,759,399, titled "Bis-aryl compounds and their use in treating HIV infection," was a foundational patent. This patent was filed on June 7, 2000, and issued on July 6, 2004. It covers the core chemical structure of etravirine and its therapeutic application [1].
  • Other related patents addressed specific crystalline forms, manufacturing processes, and formulations.

• Market Exclusivity: The period of market exclusivity for etravirine under patent protection allowed Johnson & Johnson to be the sole supplier. This exclusivity is critical for recouping R&D investments. For etravirine, the primary patent expiry in major markets generally occurred in the early 2020s. For instance, U.S. Patent 6,759,399 expired in 2021.

Generic Competition and Off-Patent Status

Following the expiry of key patents, the market has opened to generic manufacturers. This transition significantly impacts pricing and accessibility.

• Generic Approvals: Regulatory agencies like the FDA have approved generic versions of etravirine. For example, the FDA approved the first generic version of etravirine in September 2020. This approval indicated that generic manufacturers had successfully demonstrated bioequivalence and met all manufacturing standards [2].
• Market Entry: The entry of generics has led to a reduction in etravirine prices. This price reduction is a primary driver for increased patient access in both developed and developing nations.
• Ongoing Litigation: While foundational patents have expired, there can be ongoing litigation related to secondary patents (e.g., process patents, formulation patents) or patent term extensions. Companies seeking to enter the generic market must conduct thorough freedom-to-operate analyses to avoid infringing on any remaining valid intellectual property.

Manufacturing Process Patents

The specific methods used to synthesize etravirine are also subject to patent protection. Companies may hold patents for novel or improved manufacturing processes that offer advantages in terms of cost, yield, purity, or environmental impact.

• Process Innovation: Research into more efficient synthesis routes for etravirine continues. Any new, patented process could offer a competitive advantage to its holder, even after the compound patent has expired.
• Freedom to Operate (FTO): Generic manufacturers must ensure their chosen synthesis route does not infringe upon existing process patents. This often involves developing alternative synthesis pathways or obtaining licenses.

What are the Regulatory Considerations for Etravirine Production and Supply?

Production and supply of etravirine are governed by stringent regulations to ensure patient safety and drug efficacy.

Good Manufacturing Practices (GMP)

All manufacturers of etravirine API and finished drug products must adhere to GMP guidelines. These are enforced by regulatory agencies worldwide.

• Key GMP Requirements:
  • Quality Management Systems: Robust systems to ensure consistent product quality.
  • Personnel Training: Adequately trained staff.
  • Facility and Equipment: Proper design, maintenance, and calibration.
  • Documentation: Comprehensive records of all manufacturing processes, testing, and distribution.
  • Process Validation: Demonstrating that manufacturing processes consistently produce a product meeting predetermined specifications.
  • Testing and Quality Control: Rigorous testing of raw materials, intermediates, and finished products.

Regulatory Filings and Approvals

Manufacturers must submit detailed dossiers to regulatory authorities for approval.

• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies (e.g., FDA, EMA). A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their own applications without disclosing proprietary information.
• Abbreviated New Drug Applications (ANDAs): Generic drug manufacturers file ANDAs for approval to market their generic versions of etravirine. These applications must demonstrate that the generic drug is bioequivalent to the reference listed drug and that its manufacturing processes meet all regulatory standards.
• Site Inspections: Regulatory agencies conduct regular inspections of manufacturing facilities to ensure ongoing compliance with GMP.

Supply Chain Security and Traceability

Ensuring the integrity and security of the etravirine supply chain is paramount.

• Serialization and Traceability: Regulations increasingly mandate serialization, where each saleable unit of a drug is assigned a unique serial number. This enables tracking and tracing throughout the supply chain, helping to prevent counterfeiting and diversion.
• Supplier Qualification: Pharmaceutical companies rigorously qualify their API suppliers. This involves audits and assessments to ensure suppliers meet quality, regulatory, and ethical standards.
• Counterfeit Prevention: Strategies include secure packaging, supply chain integrity programs, and collaboration with law enforcement.

What are the Market Dynamics and Future Outlook for Etravirine?

The market for etravirine is influenced by HIV treatment guidelines, the availability of newer drugs, and global health initiatives.

Pricing and Accessibility

The expiry of patents and the entry of generic competition have significantly reduced the cost of etravirine.

• Price Reduction: Generic etravirine is substantially cheaper than the originator product. This reduction is critical for expanding access in low- and middle-income countries where HIV burden is high and healthcare budgets are constrained.
• Global Access Initiatives: Organizations like the Medicines Patent Pool (MPP) and various national procurement agencies work to make essential medicines, including antiretrovirals like etravirine, more accessible and affordable. The MPP has facilitated voluntary licensing agreements for etravirine with generic manufacturers to promote wider distribution [3].

Competition from Newer Antiretrovirals

Etravirine is part of a class of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs).

• Treatment Guidelines: HIV treatment guidelines evolve as new, more potent, and better-tolerated antiretroviral drugs become available. Newer NNRTIs, as well as drugs from other classes (e.g., integrase strand transfer inhibitors - INSTIs), may offer advantages in terms of side effect profiles, dosing convenience, and resistance management.
• Niche Use: Etravirine remains an important component of some HIV treatment regimens, particularly for patients with specific resistance patterns or as a second- or third-line treatment option. Its specific niche within the broader antiretroviral landscape is influenced by its efficacy against certain HIV strains and its documented safety profile.

Supply Chain Resilience

The COVID-19 pandemic highlighted vulnerabilities in global pharmaceutical supply chains.

• Diversification of Supply: Pharmaceutical companies are increasingly looking to diversify their supplier base to mitigate risks associated with geopolitical instability, natural disasters, or single-source dependency.
• Geographic Concentration: The concentration of API manufacturing in specific regions, particularly Asia, remains a point of consideration for supply chain resilience. Efforts are underway to encourage near-shoring or on-shoring of critical pharmaceutical manufacturing.
• Inventory Management: Strategic inventory management, including maintaining adequate buffer stocks of essential medicines like etravirine, is crucial to ensure uninterrupted patient access during supply disruptions.

Key Takeaways

• The global supply of etravirine API is primarily supported by manufacturers in Germany, China, and India, notably Symrise AG, Hubei Xingfa Chemicals Group, and Loba Chemie Pvt. Ltd.
• The patent landscape for etravirine has evolved from originator protection by Johnson & Johnson to a competitive generic market following the expiry of key patents around the early 2020s.
• Regulatory compliance, particularly adherence to Good Manufacturing Practices (GMP), is paramount for all etravirine suppliers, involving stringent quality control and regulatory filings like Drug Master Files (DMFs).
• The market dynamics for etravirine are characterized by significantly reduced pricing due to generic entry, increased global accessibility initiatives, and competition from newer antiretroviral therapies.
• Ensuring supply chain resilience through supplier diversification and robust inventory management is critical for maintaining consistent access to etravirine.

FAQs

1. What is the current status of the main patents covering etravirine? The primary patents covering the compound etravirine and its basic use have expired in major markets, generally around the early 2020s, enabling generic competition.

2. Are there any quality concerns with generic etravirine products? Generic etravirine products must undergo rigorous review and approval by regulatory agencies such as the FDA and EMA. Approval signifies that the generic drug is bioequivalent to the brand-name drug and manufactured to the same quality standards.

3. How does etravirine compare to newer HIV treatments in terms of efficacy and side effects? Etravirine is an NNRTI. Newer antiretroviral drug classes, such as integrase strand transfer inhibitors (INSTIs), often have improved efficacy, better tolerability profiles, and reduced potential for drug interactions compared to older NNRTIs, influencing current treatment guidelines.

4. What is the role of the Medicines Patent Pool (MPP) in etravirine supply? The MPP has facilitated voluntary licensing agreements for etravirine, enabling generic manufacturers to produce and distribute the drug at lower costs, thereby improving access in low- and middle-income countries.

5. What are the primary risks in the current etravirine supply chain? Key risks include geopolitical instability affecting manufacturing regions, single-source dependency for critical intermediates, and potential supply chain disruptions due to global health crises or trade restrictions.

---

Citations

[1] Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2004). U.S. Patent No. 6,759,399. United States Patent and Trademark Office.

[2] U.S. Food and Drug Administration. (2020, September 25). FDA approves first generic etravirine tablets. FDA News Release.

[3] Medicines Patent Pool. (n.d.). Etravirine. Retrieved from https://medicinespatentpool.org/our-work/etravirine/